Skip to content

Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients.

The Relationship Between EPO Resistance and Sirtuin-1 Levels in Hemodialysis Patients.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06877286
Enrollment
391
Registered
2025-03-14
Start date
2020-08-01
Completion date
2021-10-15
Last updated
2025-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia in End Stage Renal Disease, Chronic Kidney Disease, Erythropoietin, Hemodialysis

Brief summary

This study investigates the relationship between Sirtuin-1 (SIRT1) levels and erythropoietin resistance in hemodialysis patients. The study aims to determine whether low SIRT1 levels contribute to EPO resistance and to explore the potential mechanisms involved. Blood samples and clinical data from hemodialysis patients will be analyzed to evaluate this relationship.

Detailed description

This study explores the association between Sirtuin-1 (SIRT1) levels and erythropoietin resistance in hemodialysis patients. Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia in chronic kidney disease (CKD) patients undergoing hemodialysis. However, a significant proportion of patients exhibit hyporesponsiveness to ESAs, leading to suboptimal anemia management. SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase, regulates hypoxia and iron metabolism by modulating the activity of hypoxia-inducible factor 1α (HIF-1α). Lower SIRT1 levels may impair HIF-1α activity and contribute to reduced erythropoietin (EPO) responsiveness. In this multicentric cross-sectional cohort study, 391 adult hemodialysis patients from provincial dialysis clinics in Bursa, Turkey, were enrolled between August 2020 and March 2021. ESA responsiveness was assessed using the Erythropoietin Resistance Index (ERI), calculated as the weekly weight-adjusted ESA dose divided by hemoglobin concentration. Serum SIRT1 levels were measured using a human SIRT1 ELISA kit. The study aims to determine whether low SIRT1 levels are independently associated with higher ERI scores and to identify other clinical and biochemical parameters influencing ESA responsiveness. Multiple regression and correlation analyses will be performed to evaluate the relationship between SIRT1 levels, ERI scores, ferritin levels, and other clinical factors. Logistic regression will also be conducted to explore whether SIRT1 is an independent predictor of high ERI scores (≥50th percentile). The findings from this study may provide new insights into the molecular mechanisms underlying ESA resistance and highlight the potential role of SIRT1 as a target for improving anemia management in hemodialysis patients.

Interventions

DIAGNOSTIC_TESTSirtuin-1 Level Measurement

Measurement of serum Sirtuin-1 levels using ELISA in hemodialysis patients to evaluate the relationship between Sirtuin-1 levels and erythropoietin resistance

Sponsors

Bursa Yuksek Ihtisas Training and Research Hospital
CollaboratorOTHER_GOV
Cuma Bulent Gul
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged ≥18 years * Receiving hemodialysis * Availability of laboratory data to calculate ERI

Exclusion criteria

* Autosomal polycystic kidney disease * Malignancies * Infectious diseases * Chronic rheumatological disorders * Vitamin B12 or folic acid deficiency * CRP levels ≥ 5 mg/L * PTH levels ≥ 300 pg/dL * Inadequate hemodialysis (Kt/Vurea \< 1.2)

Design outcomes

Primary

MeasureTime frameDescription
Sirtuin-1 levelsMeasured at baseline (initial blood sample)Measurement of serum Sirtuin-1 levels using ELISA to evaluate its association with erythropoietin resistance.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026